Sunday, June 26, 2022

Insider Selling: Cheng Sohanya Roshan, Karyopharm Therapeutics Inc. [KPTI] Chief Commercial Officer divested 1,551 shares

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Karyopharm Therapeutics Inc. shares valued at $8,075 were sold by Cheng Sohanya Roshan on Jun 13. At $5.21 per share, Cheng Sohanya Roshan sold 1,551 shares. The insider’s holdings dropped to 89,949 shares worth approximately $0.43 million following the completion of this transaction.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Also, PAKIANATHAN DEEPIKA sold 1,307 shares, netting a total of over 7,844 in proceeds. Following the sale of shares at $6.00 each, the insider now holds 16,673 shares.

Before that, PAKIANATHAN DEEPIKA had sold 211,500 shares from its account. In a trade valued at $1,307,028, the Director traded Karyopharm Therapeutics Inc. shares for $6.18 each. Upon closing the transaction, the insider’s holdings decreased to 211,500 shares, worth approximately $80092.8.

As published in a research note from JP Morgan on February 09, 2022, Karyopharm Therapeutics Inc. [KPTI] has been rated up from an Underweight to a Neutral and the price target has been revised to $8. This represents a 40.0% premium over Wednesday’s closing price. As of August 06, 2021, SVB Leerink has decreased its “an Outperform” rating to a “Mkt perform” for KPTI. Earlier on August 06, 2021, RBC Capital Mkts downgraded its rating. Their new recommendation was “a Sector perform” for KPTI stock which previously was a “an Outperform”.

Analyzing KPTI’s Price Performance

On Wednesday, Karyopharm Therapeutics Inc. [NASDAQ: KPTI] plunged -1.44% to $4.80. The stock’s lowest price that day was $4.72, but it reached a high of $5.17 in the same session. During the last five days, there has been a surge of approximately 5.03%. Over the course of the year, Karyopharm Therapeutics Inc. shares have dropped approximately -25.35%. Shares of the company reached a 52-week high of $14.73 on 02/18/22 and a 52-week low of $4.02 on 06/16/22. A 50-day SMA is recorded $6.02, while a 200-day SMA reached $6.99. Nevertheless, trading volume fell to 2.69 million shares from 2.92 million shares the previous day.

Support And Resistance Levels for Karyopharm Therapeutics Inc. (KPTI)

According to the 24-hour chart, there is a support level at 4.62, which, if violated, would cause prices to drop to 4.45. In the upper region, resistance lies at 5.07. The next price resistance is at 5.35. RSI (Relative Strength Index) is 41.34 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.62, which suggests the price will decrease in the coming days. Percent R is at 72.34%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.

Which companies own the most shares of Karyopharm Therapeutics Inc. (KPTI)?

According to SSgA Funds Management, Inc. filings, the company currently owns 10,966,701 shares, which is about 13.81% of the total KPTI shares outstanding. The investor’s shares have appreciated by 5,453,021 from its previous 13-F filing of 5513680.0 shares. With the completion of the sale, BlackRock Fund Advisors’s stake is now worth $35,315,505. Palo Alto Investors LP acquire a 2.76% interest valued at $35.3 million while Commodore Capital LP purchased a 450,000 stake. A total of 599,916 shares of Karyopharm Therapeutics Inc. were bought by The Vanguard Group, Inc. during the quarter, and 825,000 were bought by Rubric Capital Management LP. In its current portfolio, Iron Triangle Partners LP holds 2,000,000 shares valued at $12.56 million.

In terms of Karyopharm Therapeutics Inc. share price expectations, FactSet research, analysts set an average price target of $11.89 in the next 12 months, up nearly 105.34% from the previous closing price of $4.87. Analysts anticipate Karyopharm Therapeutics Inc. stock to reach $21.00 by 2022, with the lowest price target being $5.00. In spite of this, 9 analysts ranked Karyopharm Therapeutics Inc. stock as an Overweight at the end of 2022.

Latest news

Related news

LEAVE A REPLY

Please enter your comment!
Please enter your name here

2618

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam